<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00607828</url>
  </required_header>
  <id_info>
    <org_study_id>337-07</org_study_id>
    <secondary_id>P30CA036727</secondary_id>
    <secondary_id>UNMC-33707</secondary_id>
    <nct_id>NCT00607828</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer</brief_title>
  <official_title>Feasibility of Hypofractionated Stereotactic Radiotherapy in Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor&#xD;
      and cause less damage to normal tissue.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic&#xD;
      radiation therapy in treating patients with advanced liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the safety of hypofractionated stereotactic radiotherapy (SRT) in patients&#xD;
           with advanced hepatocellular carcinoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the maximum tolerated dose of SRT in these patients.&#xD;
&#xD;
        -  To determine the objective tumor response rate in terms of the percentage of tumor size&#xD;
           change on CT, percentage of intensity change on MRI, and the percentage of change in&#xD;
           alfa fetoprotein in patients treated with this therapy.&#xD;
&#xD;
        -  To determine the value of 4-dimensional CT in liver cancer planning in terms of the&#xD;
           extent of liver motion (three dimensionally) and the percentage of patients requiring&#xD;
           breath gating due to the amplitude of organ motion exceeding 1 cm in any dimension.&#xD;
&#xD;
        -  To determine the value of breath gating in liver cancer SRT in terms of the success rate&#xD;
           of breath gating and the percentage of treatment time prolongation secondary to the&#xD;
           gating.&#xD;
&#xD;
      OUTLINE: Patients undergo hypofractionated stereotactic radiotherapy once daily on days 1-5.&#xD;
&#xD;
      After completion of study therapy, patients are followed at 1 and 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">February 15, 2017</completion_date>
  <primary_completion_date type="Actual">February 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity as assessed by NCI CTCAE v3.0</measure>
    <time_frame>Up to 1 month after SRT</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>At least 1 month of observation after surgery</time_frame>
  </primary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiation therapy</intervention_name>
    <description>Undergo radiotherapy</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 unidimensionally target lesion that can be&#xD;
             accurately measured by CT scan or MRI according to RECIST and must have a maximum&#xD;
             diameter ≤ 8 cm&#xD;
&#xD;
          -  No known CNS tumors, including metastatic brain disease&#xD;
&#xD;
          -  Child-Pugh class A-B cirrhotic status&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  WBC ≥ 2,000/μL&#xD;
&#xD;
          -  Platelet count ≥ 60,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
          -  INR ≤ 2.3&#xD;
&#xD;
          -  No malignancy within the past 3 years that is distinct in its primary site or&#xD;
             histology from HCC, except for carcinoma in situ of the cervix, treated basal cell&#xD;
             carcinoma, or superficial bladder tumors (i.e., Ta, Tis, and T1), or any other cancer&#xD;
             that has been curatively treated &gt; 3 years prior to study entry&#xD;
&#xD;
          -  No renal failure requiring hemodialysis or peritoneal dialysis&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection &gt; grade 2&#xD;
&#xD;
               -  NYHA class II-IV congestive heart failure&#xD;
&#xD;
               -  Active coronary artery disease&#xD;
&#xD;
               -  Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or&#xD;
                  digoxin&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Condition that could jeopardize the safety of the patient or study compliance&#xD;
&#xD;
          -  More than 6 months since prior myocardial infarction&#xD;
&#xD;
          -  No history of variceal bleeding where the varices have not been eradicated or&#xD;
             decompressed by shunt placement&#xD;
&#xD;
          -  No condition that would prevent the patient from undergoing marker implantation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No substance abuse, medical, psychological, or social condition that may interfere&#xD;
             with the patient's participation in the study or evaluation of the study results&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Prior systemic chemotherapy allowed&#xD;
&#xD;
          -  At least 6 weeks since prior non-radiation local therapy (e.g., surgery, hepatic&#xD;
             arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol&#xD;
             injection, or cryoablation)&#xD;
&#xD;
          -  No prior radiotherapy to the liver&#xD;
&#xD;
          -  Concurrent therapeutic anticoagulation (e.g., warfarin or heparin) allowed provided&#xD;
             that no prior evidence of underlying abnormality in PT, PTT, INR exists&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chi Lin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-6805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>February 1, 2008</study_first_submitted>
  <study_first_submitted_qc>February 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <last_update_submitted>September 23, 2017</last_update_submitted>
  <last_update_submitted_qc>September 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Chi Lin, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

